Prophylaxis
Dr. Cindy Leissinger is currently Professor of Medicine, and Clinical Professor of Pediatrics and Pathology at Tulane University and is the Director Emeritus of the Louisiana Center for Bleeding and Clotting Disorders. She is a fellow of the American College of Physicians and a member of the American Society of Hematology. Dr. Leissinger has been a member of the Hemostasis and Thrombosis Research Society since its inception and has served the society in numerous leadership positions, recently concluding a term as the society’s president.
Dr. Leissinger received her medical degree from Tulane University School of Medicine. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at The National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.
In addition to caring for patients with coagulation disorders, Dr. Leissinger oversees an active research program that receives funding from the National Institutes of Health as well as numerous other federal and industry sources. She participates in several clinical research groups and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.
1. Leissinger C, Josephson C, Granger S, Konkle B, Kruse-Jarres R, Ragni M, Journeycake J, Neufeld E, Marder V, Assmann S, for the RICH Study Investigators. Rituximab for the treatment of inhibitors in hemophilia A: A phase II study. Thromb Haemost. 2014 Jun; 12;112(3).
2. Leissinger C, Carcao M, Gill J, Journeycake J, Singleton T, Valentino L. Desmopressin (DDAVP) in the management of patients with bleeding disorders. Haemophilia. 2014 Mar;20(2):158-67.
3. Gringeri A, Leissinger C, Cortesi P, Jo H, Fusco F, Riva S, Mantovani L, and the ProFEIBA Study Group. Health related quality of life in patients with haemophilia and inhibitors on prophylaxis with an anti-inhibitor complex concentrate (AICC): Results from the ProFEIBA Study. Haemophilia. 2013 Sep;19(5):736-43.
4. Leissinger C, Gringeri A, Antmen B, Berntorp B, Biasoli B, Carpenter C, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Négrier C, Rocino A, Schramm W, Serban M, Uscatescu M, Windyga J, Zülfikar B, Mantovani L. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011 Nov;365:1684-92.
5. Leissinger C, Cooper D and Wilke C. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe hemophilia A. Haemophilia. 2011 Nov; 17(6):884-889.